An FDA advisory panel gave unexpectedly strong support to Qnexa, a diet pill from Vivus ($VVUS) that would be the first new weight loss pill to hit the U.S. market in 13 years. Analysts now consider FDA approval as "pretty much a done deal," as Vivus now shifts focus to gearing up for a launch. Report